Detalhe da pesquisa
1.
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Oncologist
; 26(3): 242-249, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33486852
2.
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Oncologist
; 26(1): 70-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179377
3.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Blood
; 133(25): 2664-2668, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31010846
4.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31484647
5.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Blood
; 126(7): 858-62, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089396
6.
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 20(1): 66-72, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24141006
7.
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Biol Blood Marrow Transplant
; 19(4): 597-601, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23305680
8.
Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.
Haematologica
; 98(3): 437-43, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22899581
9.
European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006-2020.
Clin Pharmacol Ther
; 114(1): 148-160, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129347
10.
Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation.
Transfusion
; 52(5): 1086-91, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22023454
11.
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): e844-e852, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688793
12.
Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients.
Biol Blood Marrow Transplant
; 17(11): 1653-61, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21586334
13.
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
Eur J Haematol
; 84(4): 359-61, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20002730
14.
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
J Clin Oncol
; 38(8): 784-792, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31770060
15.
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
PLoS One
; 13(9): e0203392, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30192814
16.
Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry.
Clin Lymphoma Myeloma Leuk
; 11(1): 93-5, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21454201